<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190385</url>
  </required_header>
  <id_info>
    <org_study_id>AOM03009</org_study_id>
    <nct_id>NCT00190385</nct_id>
  </id_info>
  <brief_title>Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis</brief_title>
  <official_title>Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis. A Randomized Trial Comparing Two Periodicities of Ultrasonographic Surveillance: 3-month vs 6-month</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver carcinoma is becoming the main complication of cirrhosis. Treatment of symptomatic or
      large tumors is disappointing. Regular ultrasonographic screening of small (curable) tumors
      is currently recommended, but the best periodicity is unknown.This randomized trial is aimed
      to compare 6-month (current recommendation) and 3-month ultrasonographic screenings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients: All consecutive patients with compensated HBV, HCV, alcohol or
      hemochromatosis-related cirrhosis (without any previous clinical complication including liver
      cancer).

      Randomization: factorial: ultrasonography (3-month versus 6-month); serum alfa-fetoprotein
      assay (none versus 6-month).

      End points: rate of small tumors (first main criteria); survival (second main criteria).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of small hepatocellular carcinoma (HCC)</measure>
    <time_frame>6 months versus 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical value of serum alfa-fetoprotein assay</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1200</enrollment>
  <condition>Compensated Cirrhosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasonographic screening</intervention_name>
    <description>Ultrasonographic screening</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Compensated cirrhosis

        Exclusion Criteria:

          -  Antecedent of osmic acid synoviorthesis or of isotopic synoviorthesis of the studied
             knee

          -  Intra-articular injection of triamcinolone hexacetonide in three months preceding the
             inclusion or by a different corticoid in the month preceding the inclusion

          -  Evolutionary infectious or neoplastic pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Trinchet, Pr, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Jean Verdier</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>February 24, 2011</last_update_submitted>
  <last_update_submitted_qc>February 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sylla KHAOUSSOU</name_title>
    <organization>Department of Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Screening</keyword>
  <keyword>Randomized</keyword>
  <keyword>HBV</keyword>
  <keyword>HCV</keyword>
  <keyword>alcohol</keyword>
  <keyword>hemochromatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

